GEN Exclusives

More »

GEN News Highlights

More »
Dec 17, 2007

Crucell Inks Research License Agreement with ProFibrix on STAR

  • Crucell entered into a nonexclusive STAR® research license agreement with ProFibrix covering the production of specific forms of human fibrinogen.

    According to Crucell, STAR technology is a production method that is particularly useful for the production of recombinant human antibodies and proteins.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »